A number of other research analysts have also recently commented on the company. TD Securities reissued a hold rating and issued a C$4.75 target price on shares of Cipher Pharmaceuticals in a research note on Tuesday, May 2nd. Bloom Burton reaffirmed a hold rating on shares of Cipher Pharmaceuticals in a research note on Monday, February 13th.
Cipher Pharmaceuticals (TSE CPH) traded up 0.18% during trading on Friday, reaching $5.55. The company’s stock had a trading volume of 17,420 shares. The firm’s market cap is $147.14 million. The stock’s 50 day moving average is $5.31 and its 200-day moving average is $4.69. Cipher Pharmaceuticals has a 52 week low of $3.50 and a 52 week high of $7.35.
In related news, insider John Mull acquired 5,000 shares of the stock in a transaction on Tuesday, June 13th. The stock was acquired at an average cost of C$5.55 per share, for a total transaction of C$27,750.00. Also, Director Harold Morton Wolkin bought 23,700 shares of the stock in a transaction dated Wednesday, May 17th. The shares were acquired at an average price of C$5.45 per share, with a total value of C$129,165.00. Over the last quarter, insiders have bought 87,900 shares of company stock valued at $485,425.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
What are top analysts saying about Cipher Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cipher Pharmaceuticals Inc and related companies.